The VESL Wall, Issue #3 is now out! This month, the theme is “strength in numbers” as we explore a pooled analysis of three phase 3 studies as well as large international cohorts used to analyze food intake and cardiovascular outcomes.

~ veslcommunity

The VESL Wall Issue #3 was sent to all VESL members by email on Tuesday, May 11, and can be accessed online here.

View Dr. Grace Chua’s 13-minute video summary of VESL Wall Issue #3 here: http://bit.ly/VidVESLWall3

To view all archived issues of the VESL Wall, go to veslcommunity.org/the-vesl-wall

The second episode of Lipid Leaders is now out! We’re honoured to speak with Dr. Ruth McPherson about her ground-breaking research and contributions to the Canadian lipid and cardiovascular community.

~ veslcommunity

In this episode of Lipid Leaders, Dr. Robert Hegele speaks with Dr. Ruth McPherson, MD, PhD, FRCPC, FACP, FRSC, Director of the Ruddy Canadian Cardiovascular Genetics Centre, Atherogenomics Laboratory and the Lipid Clinic at the University of Ottawa Heart Institute.

>> View the video [18 min]

Episode #2 of Lipid Leaders was sent to all VESL members by email on Monday, May 10, and can be accessed online here.

New Lipid Leaders interviews will be released bi-weekly; view archived interviews at veslcommunity.org/lipid-leaders.

Introducing “Lipid Leaders”, a feature of the VESL community where we highlight the important work of researchers in the Canadian lipid and cardiovascular community. In this first edition, we’re honoured to chat with Dr. Jacques Genest.

~ veslcommunity

We’re delighted to announce the launch of Lipid Leaders, a new feature of the VESL community where we highlight the important work of researchers in the Canadian lipid and cardiovascular community.

In the first edition of Lipid Leaders, Dr. Samer Mansour speaks with Dr. Jacques Genest, MD, FRCP(C), gaining personal insights into his remarkable journey in research. Dr. Genest is a professor of Medicine at McGill University and staff Cardiologist at the McGill University Health Centre.

>> View the video in English [10 min]

>> Regardez la vidéo en français [10 min]

This first issue of Lipid Leaders was sent to all VESL members by email on Monday, April 26, and can be accessed online here.

New interviews will be released bi-weekly; view all interviews to date at veslcommunity.org/lipid-leaders.

The VESL Wall, Issue #2 is now available! This month we explore the cardiovascular and renal protective effects of SGLT2i in patients with and without diabetes, and the unique challenges of cardiovascular health in the developing world.

~ veslcommunity

The VESL Wall Issue #2 was sent to all VESL members by email on Monday, March 29, and can be accessed online here.

View Dr. Robert Hegele’s 10-minute video summary here.

To view all issues of the VESL Wall, go to veslcommunity.org/the-vesl-wall

Introducing the “VESL Wall”, a monthly selection of articles for the VESL community with highlights of clinical impact and Canadian perspective

~ veslcommunity

Welcome to the inaugural edition of the VESL Wall. Each month we will feature a few articles recently posted in the VESL community and highlight their clinical impact and Canadian perspective.

The first issue of the VESL Wall, including a video summary by Dr. Liam Brunham, was sent to all VESL members by email on March 1, and can be accessed online here.

Launch of the VESL Community

~ veslcommunity

We’re pleased to announce the launch of a new initiative called VESL (Virtual Engagement Social Learning), an online learning community for Canadian healthcare professionals with an interest in atherosclerotic cardiovascular disease.

VESL will foster open scientific discussions through online forums, webinars and micro-learning objects, to sustain ongoing connection anchored in scientific discovery and expert insight. It is our hope that this enhanced collaboration will advance understanding in this field and support the highest level of care for patients in Canada.

Members of VESL will receive a weekly email digest with a summary of newly-released scientific articles from VESL members, curated content from sources identified by the VESL faculty, as well as periodic learning opportunities including structured questions to initiate forum discussions, and polling questions to augment community discussions.

LegitiMed will be managing this virtual community residing on Sosido (www.sosido.com).

We are interested in a full exchange of ideas around this subject. So, if you know others who would be interested in participating in the VESL community, we welcome your referrals/recommendations.

We thank Novartis Canada for their support of this initiative.

The VESL community is designed for the scientific exchange of information between Healthcare Professionals and is made possible with financial support from Novartis Canada. Novartis does not itself monitor the discussions. However, a third-party service provider does review the discussions only for the purpose of identifying any potential AE discussion. This review is required since as a drug manufacturer, Novartis has a regulatory obligation to report any AE that (directly or indirectly) comes to their attention. The third-party will only report the potential AE discussion and will include contact information. Should your post be reported to patient safety, you will be contacted by the third-party service provider to determine if you would like Novartis patient safety to contact you for more details.